US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns
Drug price increases have contributed significantly to US revenue growth, about 61% for the 45 largest pharmaceutical products sold over the last three years, according to an analysis by Leerink. Investors should brace for declining growth rates for certain products that generate the bulk of their sales in the US, analyst Geoffrey Porges warned.
You may also be interested in...
We Haven’t Ruled Out Drug Price Increases, Says Regeneron’s Schleifer
In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Pharma companies have responded to mounting political pressure to lower drug prices by pledging to limit increases and even roll back the costs of certain drugs, but it's hard to keep track of who has promised what exactly. Here, Scrip provides a listing of pharma pricing pledges.
Novartis Puts A Halt To Drug Price Increases While Awaiting More On Trump's Blueprint
Novartis joined Pfizer in agreeing to hold off on any further US drug price increases this year, saying the decision was prudent in the current environment. On Trump's drug pricing blueprint, Novartis said it is carefully monitoring how policy evolves this year before charting a course for 2019.